Targeting the ‘Guards’: A New Immunotherapy Approach to Dismantle Cancer’s Defenses
For years, one of the greatest hurdles in oncology has been the “fortress” created by solid tumors. While immunotherapy has revolutionized the treatment of many cancers, many aggressive, metastatic diseases—particularly lung and ovarian cancers—remain stubbornly resistant. The problem isn’t just the cancer cells themselves. it’s the protective environment they build around themselves.
However, researchers at the Icahn School of Medicine at Mount Sinai are pioneering a “Trojan horse” strategy that shifts the focus from attacking cancer cells directly to neutralizing the very cells that protect them. This experimental immunotherapy, detailed in the journal Cancer Cell, offers a potential breakthrough for treating advanced solid tumors that have evaded traditional treatments.
The Problem: The Tumor’s Walled Fortress
In a healthy body, immune cells called macrophages act as first responders, cleaning up debris and fighting infections. But within a tumor, these cells are often “reprogrammed.” Instead of attacking the malignancy, they become tumor-associated macrophages (TAMs), acting as guardians that shield cancer cells from the immune system and even help the disease spread.
“What we call a tumor is really cancer cells surrounded by cells that feed and protect them. It’s a walled fortress,” explains Jaime Mateus-Tique, PhD, a faculty member in Immunology and Immunotherapy at the Icahn School of Medicine at Mount Sinai. He notes that traditional immunotherapy often fails because it simply cannot get past these cellular “guards.”
The Solution: Armored CAR T Cells
To breach this fortress, the Mount Sinai team has reengineered CAR T cells—immune cells modified to recognize specific targets. While traditional CAR T therapies are designed to hunt for specific markers on cancer cells, this new approach directs the cells to recognize and target the tumor-associated macrophages instead.
This “armored” approach includes two critical components:
- Selective Targeting: The therapy is designed to remove tumor-associated macrophages while leaving healthy macrophages in the rest of the body intact.
- IL-12 Release: The engineered CAR T cells are modified to release interleukin-12 (IL-12), a potent immune-stimulating molecule. This release helps transform the tumor environment from one that suppresses the immune system to one that actively promotes it.
By targeting the macrophages, the treatment effectively “turns the foe into an ally,” as described by Brian Brown, PhD, Director of the Icahn Genomics Institute. Once the protective shield is removed, the body’s own killer T cells can move in to destroy the cancer cells.
Preclinical Success and the “Antigen-Independent” Advantage
In preclinical models involving aggressive metastatic lung and ovarian cancer, the results were significant. Mice treated with these engineered cells lived months longer than untreated subjects, with many achieving complete remission.
One of the most promising aspects of this research is that the strategy is antigen-independent. Because the therapy targets the macrophages—which are present in almost every type of tumor—it does not rely on identifying specific, unique markers on every individual cancer cell. This suggests the approach could potentially be applied to a wide variety of solid tumors that currently lack effective immunotherapeutic options.
Key Takeaways: A New Frontier in Immunotherapy
| Feature | Traditional CAR T Therapy | Macrophage-Targeted CAR T |
|---|---|---|
| Primary Target | Specific cancer cell antigens | Tumor-associated macrophages (TAMs) |
| Mechanism | Directly kills cancer cells | Resets/reprograms the tumor environment |
| Applicability | Limited by specific cancer markers | Broadly applicable (antigen-independent) |
| Core Strategy | Direct attack | “Trojan Horse” / Removing the shield |
What Lies Ahead
While these findings represent a significant proof of concept, the research team emphasizes that this is not yet a cure for humans. The next critical phase involves determining the safety and efficacy of this therapy in clinical human trials. Currently, researchers are focusing on refining how and where IL-12 is released within the tumor to maximize impact while minimizing potential side effects.
If successful, this method could fundamentally change how we approach metastatic disease, moving away from trying to find a single “key” for every cancer and instead focusing on dismantling the environments that allow cancer to thrive.